Harrow closes TYRVAYA buy from Viatris for up to $100M
Harrow has completed its acquisition of TYRVAYA nasal spray, the first and only FDA-approved nasal spray for dry eye disease, from Viatris. Harrow paid $30 million in cash at closing from cash on hand and may pay up to $70 million in milestones tied to net sales, for potential total consideration of $100 million. Harrow acquired worldwide rights except Japan, where Viatris retains commercialization and will pay royalties.
Why it matters: The deal gives Harrow a second differentiated branded dry-eye product alongside VEVYE in a large and growing U.S. market.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →